-

Thermo Fisher Scientific’s Clinical Research Business Receives ATD Award for Employee Talent Development

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been recognized as one of the best in the world for its successful enterprise learning and development programs by the Association for Talent Development (ATD), a global organization that empowers professionals to develop talent in the workplace.

The PPD clinical research business is a recipient of the 2022 ATD BEST Awards, which recognize enterprise-wide success in employee talent development. As a result of effective efforts to attract, develop and retain top talent in the industry, the business was recognized among 72 winners in the 2022 BEST Awards Winners' Circle, which includes small and large private, public and not-for-profit organizations from around the world.

“Our business continues to shape career development for our employees by identifying areas to enhance their knowledge and skills to better serve our customers and to enable colleagues to grow their careers,” said Jay Dixon, senior vice president, quality and enterprise learning, clinical research, Thermo Fisher Scientific. “Through our strategic development programs, we are enhancing our learning culture and providing our colleagues with unique opportunities for growth and success while helping to retain top talent within the industry.”

The ATD BEST Awards celebrate and honor those companies that use talent development as a strategic business tool to deliver results. Employee learning and development at the PPD clinical research business includes leadership and high-potential development, key talent programs, technical skills, and job-specific and soft skills training. One of the key offerings is the Core Professional Skills Program, also referred to as Core Pro, which helps employees develop necessary business skills and increase individual effectiveness in order to provide exceptional customer service.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The PPD clinical research business of Thermo Fisher Scientific has been recognized for its successful enterprise learning and development programs.
Release Versions

Contacts

Media:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom